Fennec Pharmaceuticals Inc.
FRX.TOTSXHealthcare● Active
$12.44
$-0.28(-2.20%)
Market Cap$355535511
P/E Ratio—
52W High$14.24
52W Low$7.59
Fennec Pharmaceuticals Inc. (FRX.TO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FRX.TO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($9.91M) | ($0.44M) | ($16.05M) | ($23.71M) | ($17.35M) |
| Depreciation & Amort. | $0.00M | $0.80M | $0.00M | $0.00M | $0.00M |
| Stock-Based Comp. | $0.00M | $5.06M | $5.35M | $4.22M | $4.01M |
| Change in Working Capital | ($15.09M) | $16.94M | ($6.78M) | $1.10M | ($0.93M) |
| Net Cash from Operations | ($14.67M) | $26.98M | ($17.14M) | ($18.06M) | ($14.22M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | ($0.18M) | ($0.08M) | ($0.19M) | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($19.82M) | ($13.00M) | $5.00M | $19.93M | $5.00M |
| Net Cash from Financing | $25.01M | ($13.62M) | $6.64M | $20.73M | $4.98M |
| Free Cash Flow | |||||
| Free Cash Flow | ($14.67M) | $26.98M | ($17.14M) | ($18.06M) | ($14.22M) |
| FCF Margin %(computed) | -32.30% | 56.75% | -80.67% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Fennec Pharmaceuticals Inc. data
About Fennec Pharmaceuticals Inc. (FRX.TO) Cash Flow Statement
Fennec Pharmaceuticals Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2025 — a FCF margin of -32.30%. Capital expenditure was $0.00B.
Frequently asked questions
FRX.TO · 4 questionsFennec Pharmaceuticals Inc. generated free cash flow of ($0.01B) for 2025, down 154.4% year-over-year.
FRX.TO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10